ClinicalTrials.gg
CompletedNCT04175522Updated Jun 30, 2020

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

A Phase 2 interventional study of Immunoglobulin G in Autoimmune Encephalitis, sponsored by Green Cross Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-06-30.

Sponsored by Green Cross Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis

02

Conditions studied

  • Autoimmune Encephalitis
03

In context

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

This study's enrollment of 23 is below the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.

Browse Autoimmune Diseases of the Nervous System studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged more than 12 years.(adolescent or adult)
  2. Subject who all three of the following diagnosis criteria for possible encephalitis have been met.

    • Subacute onset (rapid progression of less than 3 months) of working memory deficits(short-term memory loss), altered mental status, or psychiatric symptoms.
    • At least one of the following:

      • New focal CNS findings
      • Seizure not explained by a previously known seizure disorder
      • CSF pleocytosis (WBC count ≥ 5/mm2)
      • MRI features suggestive of encephalitis
    • Reasonable exclusion of alternative causes
  3. Subjects or parent/legal representative willing to provide written

Exclusion criteria

Exclusion Criteria:

  1. Subject who has received Immunoglobulin therapy within 10 weeks prior to screening
  2. Subject who has a history of or shock to ingredient of immunoglobulin
  3. Subject who has been diagnosed with IgA deficiency
  4. Subject who has renal disorder ( \< 10 ml/min) or requires dialysis
  5. Subject who has been diagnosed with hemolytic anemia or anemia from blood loss
  6. Subject who has been diagnosed with immuonological competence or immunodeficiency
  7. Subject who has high risk of thrombus or embolism (History of thrombus/embolism or cerebro/cardiovascular disorder within 3 months prior to screening)
  8. Subject who has low heart condition (Congestive heart failure > functional class Ⅱ: unstable coronary artery disease or myocardiac infarction within 3 months prior to screening)
  9. Subject who cannot prohibit the previously administrated by investigator's discretion (ex. Suspicion of steroid dependence, hypoadrenocorticism, when treatment effects are expected, etc.)
  10. Females who are pregnant or breast feeding
  11. Subject who is considered by investigator to ineligible for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Experimental

    Investigational product(IP)

    Drug: Immunoglobulin G

Interventions

  • IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.

06

What researchers measure

Primary outcomes

  1. Chage of mRS(The Modified Rankin Scale) score; 0(better) to 6(worse)

    Change of mRS score 7 days and 28 days after IP administration compared with baseline(before IP administration)

    Time frame: 28 days

Secondary outcomes

  1. Chage and improvement of mRS(The Modified Rankin Scale) score; 0(better) to 6(worse)

    Change and improvment of mRS score 14 days and 28 days after IP administration compared with baseline(before IP administration)

    Time frame: 28 days

  2. Chage and improvement of Glasgow coma scale(GCS); 3(worse) to 15(better)

    Change and improvment of Glasgow coma scale(GCS) 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)

    Time frame: 28 days

  3. Chage and improvement of Clinical Global Impression Scale-Severity; 1(better) to 7(worse)

    Change and improvment of Clinical Global Impression Scale-Severity 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)

    Time frame: 28 days

  4. Chage and improvement of Clinical Global Impression Scale-Impovement; 1(better) to 7(worse)

    Change and improvment of Clinical Global Impression Scale-Improvement 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)

    Time frame: 28 days

  5. Chage and improvement of CASE(Clinical Assessment scale of Encephalitis) score; 0(better) to 27(worse)

    Change and improvment of CASE score 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration)

    Time frame: 28 days

  6. The relationship

    The relationship between neurological scale

    Time frame: 28 days

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jun 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2019
First posted
Nov 25, 2019
StartActual
Nov 20, 2019
Primary completionActual
Jun 11, 2020
CompletionActual
Jun 11, 2020
Last update
Jun 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04175522
Responsible party
Sponsor
First posted
Nov 25, 2019
Start date
Nov 20, 2019
Primary completion
Jun 11, 2020
Completion
Jun 11, 2020
Last update
Jun 30, 2020

Study contacts

Soon Tae Lee, MD, Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion